Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.9600 -0.0400 (-4.00%)
Streaming Delayed Price Updated: 12:28 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Werewolf Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where Werewolf Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗
HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Werewolf Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel... 
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 ↗
HOWL stock results show that Werewolf Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.